Sussing safety

Idenix Pharmaceuticals Inc. had faced safety problems with more than one nucleotide analog before August 2012, when Bristol-Myers Squibb Co. reported heart and kidney toxicity, including one death, in a Phase II trial of the nucleotide NS5B polymerase inhibitor BMS-986094.